{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T02:30:03Z","timestamp":1795228203881,"version":"4.10.3"},"reference-count":42,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.vaccine.2024.126310","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T13:48:01Z","timestamp":1725976081000},"page":"126310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines"],"prefix":"10.1016","volume":"42","author":[{"given":"Laura M.","family":"King","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Lewnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126310_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae142","article-title":"Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes","author":"King","year":"2024","journal-title":"J Infect Dis Published online"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126310_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0177113","article-title":"Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis","volume":"12","author":"Balsells","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0020","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3201\/eid2706.204238","article-title":"Twenty-year public Health impact of 7- and 13-valent pneumococcal conjugate vaccines in US children","volume":"27","author":"Wasserman","year":"2021","journal-title":"Emerg Infect Dis"},{"issue":"47","key":"10.1016\/j.vaccine.2024.126310_bb0025","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1016\/j.vaccine.2009.08.045","article-title":"Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States","volume":"27","author":"Ray","year":"2009","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126310_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S1473-3099(14)71081-3","article-title":"Impact of 13-valent pneumococcal conjugate vaccine used in children on invasive pneumococcal disease in children and adults in the United States: analysis of multisite, Population-based Surveillance","volume":"15","author":"Moore","year":"2015","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0035","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S1473-3099(18)30660-1","article-title":"Making sense of differences in pneumococcal serotype replacement","volume":"19","author":"Lewnard","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"39","key":"10.1016\/j.vaccine.2024.126310_bb0040","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.15585\/mmwr.mm7239a5","article-title":"Recommendations for use of 20-valent pneumococcal conjugate vaccine in children - United States, 2023","volume":"72","author":"Updates","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2024.126310_bb0045","doi-asserted-by":"crossref","unstructured":"Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1174\u20131181. doi:10.15585\/mmwr.mm7137a3.","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"10.1016\/j.vaccine.2024.126310_bb0050","article-title":"Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"10.1016\/j.vaccine.2024.126310_bb0055","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.vaccine.2021.03.070","article-title":"Non-clinical immunological comparison of a next-generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23)","volume":"39","author":"Fairman","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126310_bb0065","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1542\/peds.2013-1071","article-title":"Clinical practice guideline for the diagnosis and management of acute bacterial sinusitis in children aged 1 to 18 years","volume":"132","author":"Wald","year":"2013","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126310_bb0070","doi-asserted-by":"crossref","first-page":"e1423","DOI":"10.1093\/cid\/ciaa1860","article-title":"Effectiveness of pneumococcal conjugate vaccines against community-acquired alveolar pneumonia attributable to vaccine-serotype Streptococcus pneumoniae among children","volume":"73","author":"Lewnard","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2024.126310_bb0075","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1016\/j.vaccine.2023.03.045","article-title":"Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States","volume":"41","author":"Prasad","year":"2023","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126310_bb0080","doi-asserted-by":"crossref","first-page":"512.e1","DOI":"10.1016\/j.cmi.2019.09.008","article-title":"Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017","volume":"26","author":"Varghese","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126310_bb0085","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in Health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126310_bb0090","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jval.2013.02.009","article-title":"QALY and Productivity Loss: Empirical Evidence for \u201cDouble Counting.\u201d","volume":"16","author":"Shiroiwa","year":"2013","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126310_bb0100","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/infdis\/jiac154","article-title":"Impact of pneumococcal conjugate vaccines on antibiotic-nonsusceptible invasive pneumococcal disease in the United States","volume":"226","author":"Bajema","year":"2022","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126310_bb0105","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/INF.0000000000000849","article-title":"Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta","volume":"34","author":"Desai","year":"2015","journal-title":"Georgia Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2024.126310_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.744742","article-title":"Transition of serotype 35B pneumococci from commensal to prevalent virulent strain in children","volume":"11","author":"Fuji","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126310_bb0115","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10096-021-04324-0","article-title":"Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015\u20132019","volume":"41","author":"Kaur","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0120","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3201\/eid2306.170071","article-title":"Invasive serotype 35B pneumococci including an expanding serotype switch lineage, United States, 2015-2016","volume":"23","author":"Chochua","year":"2017","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126310_bb0125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/cid\/ciab852","article-title":"Association of Pneumococcal Serotype with Susceptibility to antimicrobial drugs: a systematic review and Meta-analysis","volume":"75","author":"Andrejko","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126310_bb0130","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1128\/JCM.01778-16","article-title":"Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States","volume":"55","author":"Olarte","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2024.126310_bb0135","author":"Self"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126310_bb0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126310_bb0145","series-title":"Preliminary work group interpretations of EtR and next steps","author":"Kobayashi","year":"2024"},{"key":"10.1016\/j.vaccine.2024.126310_bb0150","doi-asserted-by":"crossref","unstructured":"Wassil J, Sisti M, Fairman J, et al. Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1\/2, double-masked, dose-finding, active-controlled, randomised clinical trial. Lancet Infect Dis 2023;0(0). doi:https:\/\/doi.org\/10.1016\/S1473-3099(23)00572-8.","DOI":"10.1016\/S1473-3099(23)00572-8"},{"key":"10.1016\/j.vaccine.2024.126310_bb0155","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0000000000004334","article-title":"A phase three study of the safety and immunogenicity of a four-dose series of 20-valent pneumococcal conjugate vaccine in healthy infants","author":"Senders","year":"2024","journal-title":"Pediatr Infect Dis J Published online"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126310_bb0160","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0165","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","article-title":"Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures","volume":"11","author":"Pichon-Riviere","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126310_bb0170","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.amepre.2018.09.020","article-title":"Cost effectiveness of meningococcal serogroup B vaccination in college-aged young adults","volume":"56","author":"Leeds","year":"2019","journal-title":"Am J Prev Med"},{"issue":"15","key":"10.1016\/j.vaccine.2024.126310_bb0175","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.vaccine.2017.02.010","article-title":"Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland","volume":"35","author":"Allemann","year":"2017","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126310_bb0180","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S2352-4642(18)30168-8","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study","volume":"2","author":"Pichichero","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0185","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jmii.2020.05.003","article-title":"Divergent serotype distribution between children with otitis media and those without in the pneumococcal conjugate vaccine era","volume":"53","author":"Chen","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126310_bb0190","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1097\/INF.0000000000000445","article-title":"Emergence of Streptococcus pneumoniae serogroups 15 and 35 in nasopharyngeal cultures from young children with acute otitis media","volume":"33","author":"Martin","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"39","key":"10.1016\/j.vaccine.2024.126310_bb0195","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1016\/j.vaccine.2015.08.010","article-title":"A 13-year survey of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 and PCV13 implementation","volume":"33","author":"Cohen","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0200","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18959","article-title":"Association of nonpharmaceutical interventions during the COVID-19 pandemic with invasive pneumococcal disease, pneumococcal carriage, and respiratory viral infections among children in France","volume":"5","author":"Rybak","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126310_bb0205","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3201\/eid2701.201178","article-title":"Post-13-valent pneumococcal conjugate vaccine dynamics in young children of serotypes included in candidate extended-Spectrum conjugate vaccines","volume":"27","author":"Ben-Shimol","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126310_bb0210","series-title":"Distribution of serotypes and antimicrobial susceptibility of Streptococcus pneumoniae responsible for presumed complicated otitis media among children younger than 5 years of age in the United States","author":"Grant","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126310_bb0215","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jpeds.2019.07.057","article-title":"Diversity of serotype replacement after pneumococcal conjugate vaccine implementation in Europe","volume":"213","author":"Levy","year":"2019","journal-title":"J Pediatr"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126310_bb0220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/INF.0000000000001485","article-title":"Serotypes not included in 13-valent pneumococcal vaccine as causes of acute otitis media with spontaneous tympanic membrane perforation in a geographic area with high vaccination coverage","volume":"36","author":"Marchisio","year":"2017","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126310_bb0225","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/INF.0000000000001956","article-title":"Etiology of acute otitis media and characterization of pneumococcal isolates after introduction of 13-valent pneumococcal conjugate vaccine in Japanese children","volume":"37","author":"Ubukata","year":"2018","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T13:41:39Z","timestamp":1741873299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24009927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":42,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0264410X24009927"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126310","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.11.24305684","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126310"}}